Opinion | The Battle for Faster Cures at the FDA

An editorial urges the Senate to confirm Heidi Overton as the permanent Food and Drug Administration commissioner to stabilize the agency and expedite medicine approvals.
Opinion | The Battle for Faster Cures at the FDA

A facts-only brief, written by a local AI model from this article in The Wall Street Journal, November 15, 2026. It may contain mistakes, and it is not the article: the full story is at wsj.com.

An editorial urges the Senate to confirm Heidi Overton as the permanent Food and Drug Administration commissioner to stabilize the agency and expedite medicine approvals. Health Committee Chair Bill Cassidy has set a Wednesday vote to advance her nomination, though he and other Republicans, including Senators Lisa Murkowski and Susan Collins, have expressed uncertainty about their support. The piece contends that Overton’s surgical training at Johns Hopkins and public health doctorate qualify her for the role despite political opposition. It highlights her defense of vaccine safety during her confirmation hearing and her advocacy for streamlining bureaucratic processes to compete with China in biomedical research. The editorial warns that failing to confirm her could result in the appointment of a politically driven acting commissioner, which would harm patients and invite legal challenges.

Background

  • Former FDA leaders Marty Makary and Vinay Prasad were removed earlier this year, creating a leadership vacuum that the editorial says requires a steady permanent head.
  • A former advisor to Health and Human Services Secretary Robert F. Kennedy Jr. has publicly criticized Overton for supporting the approval of Moderna’s flu shot and for alleged involvement in relaxing standards for flavored vapes.
  • Pro-life groups have urged senators to withhold confirmation until the administration reinstates in-person dispensing requirements for the abortion pill mifepristone, a move the editorial claims would jeopardize necessary votes.
  • Overton has stated that she aims to fix the “review lottery” issue, where drug approval prospects depend on randomly selected reviewers, to ensure consistent best practices across the agency.

Read the full article at wsj.com

More from Sunday, November 15:

Referenced article not yet available naddr1qqt8wu…rsmu8src


Write a comment